Artificial intelligence (AI) is set to accelerate the expansion of drug development as global tech giants enter the field. In this context, South Korean pharmaceutical and biotech companies are also increasingly engaging in AI-driven drug development.
According to industry sources, OpenAI has recently acquired the drug development management platform company Orchestra Bio, marking a significant step into the life sciences sector. Orchestra Bio has developed an AI platform that manages research schedules and progress during the drug development process, coordinating tasks between internal teams and external partners. OpenAI plans to integrate this technology and workforce with its life sciences research AI, Rosalind. This signifies a shift for AI, which has primarily been used for candidate substance discovery, to now encompass development timelines and decision-making management.
Industry experts believe that the entry of big tech into the life sciences market will drive growth in the AI drug development sector. As services expand from general AI research support to comprehensive management of the entire development process, the demand for AI adoption among pharmaceutical companies is expected to rise.
South Korean pharmaceutical firms are also applying AI in drug development. LG Chem is focusing on using AI to identify patients who are likely to respond well to treatments. On October 20, LG's AI Research Institute and the U.S. biotech venture capital firm Flagship Pioneering held the 'LG AI Bio Conference,' unveiling a strategy to refine clinical trial patient selection based on biomarkers. The goal is to develop a personalized mRNA cancer vaccine that predicts neoantigens for individual patients, with preclinical trials set for next year and clinical entry aimed for 2029.
SK Biopharm secured computational resources equivalent to 128 NVIDIA AI accelerators, known as B200, last month, intending to use them for translational research that bridges non-clinical study results to clinical development. They are utilizing cloud subscription services from SK Telecom's data center. The plan is to enhance the accuracy of candidate substance evaluation and development decision-making through integrated analysis of disease, target, and compound data.
Among AI biotech firms, Galax is gaining attention for its technology that designs proteins from scratch using AI. Galax is conducting joint research with global pharmaceutical companies such as Boehringer Ingelheim and AstraZeneca, as well as collaborating with domestic firms like LG Chem, Celltrion, and Dong-A ST. In February of this year, Galax raised 42 billion won in a Series B funding round, bringing its total investment to 68 billion won.
The government is also stepping in to provide support. The Korea Pharmaceutical and Bio Association's K-MELLODDY project is set to establish a collaborative learning platform worth 34.8 billion won from 2024 to 2028. This platform will allow pharmaceutical companies to share AI algorithms without disclosing proprietary drug development data, aiming to create models that predict drug toxicity and metabolism.
Industry insiders believe that ultimately, data will determine competitiveness. While general AI can be accessed through big tech services, creating differentiated models requires accumulating disease-specific non-clinical and clinical data. An industry representative stated, "It is crucial to demonstrate the actual figures showing reduced development timelines and improved clinical success rates due to AI adoption."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.